These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 7779463)

  • 1. Guideline limit volumes for dosing animals in the preclinical stage of safety evaluation. Toxicology Subcommittee of the Association of the British Pharmaceutical Industry.
    Hull RM
    Hum Exp Toxicol; 1995 Mar; 14(3):305-7. PubMed ID: 7779463
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Principles and practices of integrating genotoxicity evaluation into routine toxicology studies: a pharmaceutical industry perspective.
    Krishna G; Urda G; Theiss J
    Environ Mol Mutagen; 1998; 32(2):115-20. PubMed ID: 9776173
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Toxicology in the drug discovery and development process.
    Dorato MA; Buckley LA
    Curr Protoc Pharmacol; 2006 Apr; Chapter 10():Unit10.3. PubMed ID: 22294168
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety pharmacology investigations in toxicology studies: an industry survey.
    Authier S; Vargas HM; Curtis MJ; Holbrook M; Pugsley MK
    J Pharmacol Toxicol Methods; 2013; 68(1):44-51. PubMed ID: 23685201
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The rat toxicity screen.
    Fowler JS; Brown JS; Bell HA
    Pharmacol Ther B; 1979; 5(1-3):461-6. PubMed ID: 493326
    [No Abstract]   [Full Text] [Related]  

  • 6. Report of the Subcommittee on Inhalation Toxicology of the Department of Health, Education and Welfare Committee to Coordinate Toxicology and Related Programs.
    J Environ Pathol Toxicol; 1977; 1(2):353-81. PubMed ID: 553140
    [No Abstract]   [Full Text] [Related]  

  • 7. Preclinical safety evaluation of recombinant human interleukin-10.
    Rosenblum IY; Johnson RC; Schmahai TJ
    Regul Toxicol Pharmacol; 2002 Feb; 35(1):56-71. PubMed ID: 11846636
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Study design and statistical analysis of toxicokinetics: a report of JPMA investigation of case studies.
    Igarashi T; Yabe T; Noda K
    J Toxicol Sci; 1996 Dec; 21(5):497-504. PubMed ID: 9035061
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Renal studies in safety pharmacology and toxicology: A survey conducted in the top 15 pharmaceutical companies.
    Benjamin A; Gallacher DJ; Greiter-Wilke A; Guillon JM; Kasai C; Ledieu D; Levesque P; Prelle K; Ratcliffe S; Sannajust F; Valentin JP
    J Pharmacol Toxicol Methods; 2015; 75():101-10. PubMed ID: 25637943
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Methodological innovations expand the safety pharmacology horizon.
    Pugsley MK; Curtis MJ
    J Pharmacol Toxicol Methods; 2012 Sep; 66(2):59-62. PubMed ID: 22617368
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of formulation and route of administration on the systemic availability of Ex-RAD®, a new radioprotectant, in preclinical species.
    Chun AW; Freshwater RE; Taft DR; Gillum AM; Maniar M
    Biopharm Drug Dispos; 2011 Mar; 32(2):99-111. PubMed ID: 21341279
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Priorities in the development of alternative methodologies in the pharmaceutical industry.
    Jackson MR
    Arch Toxicol Suppl; 1998; 20():61-70. PubMed ID: 9442282
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High dose selection in general toxicity studies for drug development: A pharmaceutical industry perspective.
    Buckley LA; Dorato MA
    Regul Toxicol Pharmacol; 2009 Aug; 54(3):301-7. PubMed ID: 19477212
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In silico methods for early toxicity assessment.
    Merlot C
    Curr Opin Drug Discov Devel; 2008 Jan; 11(1):80-5. PubMed ID: 18175270
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety assessment of drug residues.
    Jackson BA
    J Am Vet Med Assoc; 1980 May; 176(10 Spec No):1141-4. PubMed ID: 6894293
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recommendations from a global cross-company data sharing initiative on the incorporation of recovery phase animals in safety assessment studies to support first-in-human clinical trials.
    Sewell F; Chapman K; Baldrick P; Brewster D; Broadmeadow A; Brown P; Burns-Naas LA; Clarke J; Constan A; Couch J; Czupalla O; Danks A; DeGeorge J; de Haan L; Hettinger K; Hill M; Festag M; Jacobs A; Jacobson-Kram D; Kopytek S; Lorenz H; Moesgaard SG; Moore E; Pasanen M; Perry R; Ragan I; Robinson S; Schmitt PM; Short B; Lima BS; Smith D; Sparrow S; van Bekkum Y; Jones D
    Regul Toxicol Pharmacol; 2014 Oct; 70(1):413-29. PubMed ID: 25078890
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recommendations for safety pharmacology evaluations of oligonucleotide-based therapeutics.
    Berman CL; Cannon K; Cui Y; Kornbrust DJ; Lagrutta A; Sun SZ; Tepper J; Waldron G; Younis HS
    Nucleic Acid Ther; 2014 Aug; 24(4):291-301. PubMed ID: 24946015
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Developing early formulations: practice and perspective.
    Li P; Zhao L
    Int J Pharm; 2007 Aug; 341(1-2):1-19. PubMed ID: 17658228
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular clinical safety intelligence: a system for bridging clinically focused safety knowledge to early-stage drug discovery - the GSK experience.
    Vanderwall DE; Yuen N; Al-Ansari M; Bailey J; Fram D; Green DV; Pickett S; Vitulli G; Luengo JI; Almenoff JS
    Drug Discov Today; 2011 Aug; 16(15-16):646-53. PubMed ID: 21601652
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Concomitant toxicokinetics: techniques for and interpretation of exposure data obtained during the conduct of toxicology studies.
    Dahlem AM; Allerheiligen SR; Vodicnik MJ
    Toxicol Pathol; 1995; 23(2):170-8. PubMed ID: 7569672
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.